Ganoderma lucidum

Aleksandra Milosavljevic; Jo Barnes

doi:10.1071/HC23105

RESEARCH ARTICLE (Open Access)

Previous Contents Vol 15(3)

Ganoderma lucidum

Aleksandra Milosavljevic ¹ , Jo Barnes

¹ ^*

+ Author Affiliations

- Author Affiliations

¹ School of Pharmacy, University of Auckland, Auckland, New Zealand.

^* Correspondence to: j.barnes@auckland.ac.nz

Journal of Primary Health Care 15(3) 290-292 https://doi.org/10.1071/HC23105
Published: 22 September 2023

© 2023 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)

Key references

1 Jin X, Ruiz Beguerie J, Sze DM, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev [4] 2016; CD007731.
| Crossref | Google Scholar | PubMed |

2 Ahmad R, Riaz M, Khan A, et al. Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. Phytother Res 2021; 35(11): 6030-6062.
| Crossref | Google Scholar | PubMed |

3 Swallah MS, Bondzie-Quaye P, Wu Y, et al. Therapeutic potential and nutritional significance of Ganoderma lucidum – a comprehensive review from 2010 to 2022. Food Funct 2023; 14(4): 1812-1838.
| Crossref | Google Scholar | PubMed |

4 Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev [2] 2015; CD007259.
| Crossref | Google Scholar | PubMed |

5 Heinrich M, Barnes J, Prieto-Garcia J, et al. Chapter 26, Supportive therapies for stress, ageing, cancer, and debility. Fundamentals of pharmacognosy and phytotherapy, 4th edn. (In Press). Edinburgh: Elsevier; 2024. pp. 241–248.